Risk factors
Denali Therapeutics (DNLI) risk factors
Item 1A of every Denali Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors67 risks3 new4 dropped19 reworded
Denali Therapeutics reports a larger accumulated deficit of $2.05 billion and 503 employees in 2025.
Filed Feb 26, 2026 - FY2024 10-K risk factors68 risks
Denali is a clinical-stage biopharmaceutical company with an accumulated deficit of $1.54 billion as of December 31, 2024. Operations depend heavily on the proprietary TV platform and collaborations with Biogen, Sanofi, Takeda, and others.
Filed Feb 27, 2025